Eagle Health Investments LP Sells 32,297 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Eagle Health Investments LP lessened its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 59.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 21,802 shares of the biotechnology company's stock after selling 32,297 shares during the period. United Therapeutics comprises 1.9% of Eagle Health Investments LP's holdings, making the stock its 14th largest holding. Eagle Health Investments LP's holdings in United Therapeutics were worth $7,693,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in UTHR. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in United Therapeutics by 11.4% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 32,246 shares of the biotechnology company's stock worth $11,490,000 after buying an additional 3,312 shares in the last quarter. Korea Investment CORP increased its position in shares of United Therapeutics by 6.2% in the fourth quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock worth $13,863,000 after purchasing an additional 2,300 shares during the period. Florida Financial Advisors LLC raised its stake in United Therapeutics by 6.2% in the fourth quarter. Florida Financial Advisors LLC now owns 822 shares of the biotechnology company's stock valued at $290,000 after purchasing an additional 48 shares in the last quarter. Prudential Financial Inc. lifted its position in United Therapeutics by 22.2% during the fourth quarter. Prudential Financial Inc. now owns 66,541 shares of the biotechnology company's stock worth $23,478,000 after purchasing an additional 12,104 shares during the period. Finally, Vanguard Group Inc. grew its stake in United Therapeutics by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company's stock worth $1,567,253,000 after buying an additional 32,213 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Remove Ads

Insider Buying and Selling

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of the firm's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares in the company, valued at approximately $2,703,424. This trade represents a 22.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total transaction of $3,649,100.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $940,373.07. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 72,500 shares of company stock valued at $26,134,500 over the last quarter. Insiders own 11.90% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. StockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, February 27th. UBS Group boosted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $388.25.

United Therapeutics Stock Down 1.0 %

UTHR traded down $2.92 during midday trading on Monday, hitting $304.05. 167,590 shares of the company were exchanged, compared to its average volume of 449,686. The firm has a market capitalization of $13.66 billion, a P/E ratio of 13.36, a P/E/G ratio of 0.97 and a beta of 0.64. The firm's 50 day moving average price is $340.06 and its 200-day moving average price is $355.85. United Therapeutics Co. has a 1-year low of $221.53 and a 1-year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating the consensus estimate of $6.10 by $0.09. The business had revenue of $735.90 million for the quarter, compared to analysts' expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the prior year, the business posted $4.36 earnings per share. On average, sell-side analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.